Terns Pharmaceuticals. Every tracked FinTwit mention of $TERN, newest first. 29 mentions since the first on Nov 27, 2025. See the price chart.
March 2026 · 16 mentions
Mar 25
Jacob Plieth — $MRK, a company with no CML presence, buys $TERN, a company that only pivoted to CML 2 years ago. And other surprises, via @apexonco -> https://t.co/MtOjGJmTfd $ELVN $NVS $PFE $…↗
Mar 25
Jacob Plieth — Wouldn't it be funny if we found out that, say in mid-2025 (valuation ~$1bn, before $TERN was even a thing), $ELVN received a takeover approach but turned it down.↗
Mar 25
Adam Feuerstein ✡️ — @A_May_MD If you owned $TERN since last year, do you really care?↗
Mar 25
Jacob Plieth — Based on previous form $MRK will probably now rerun the $TERN study, just to prove to itself that the data were real.↗
Mar 25
Jacob Plieth — Did $MRK ascribe any value to $TERN assets beyond TERN-701? Caroline Litchfield: our valuation is based on TERN-701.↗
Mar 25
Jacob Plieth — For those wondering if $MRK might be outbid, here are the deal termination terms from $TERN https://t.co/TbM3rWyEoG↗
Mar 25
Jacob Plieth — Fun fact: what was $TERN's initial focus, before it pivoted to CML? $MRK https://t.co/HsWxFnO6Uv↗
Adam Feuerstein ✡️ — The $TERN data from December that enticed $MRK
https://t.co/51H9opufDT↗
Mar 25
Adam Feuerstein ✡️ — $MRK buying $TERN for $6.7 billion, or $53 per share.
https://t.co/N9SjDxTx50↗
Mar 25
Adam Feuerstein ✡️ — @JacobPlieth Agreed. The $TERN data were the belle of the ASH25 ball.↗
Mar 25
Jacob Plieth — @adamfeuerstein I've not run the numbers, so won't comment specifically on valuation, but:
- $TERN early data at #ASH25 were outstanding.
- companies have previously spent $6bn on…↗
Mar 25
Adam Feuerstein ✡️ — Not here how to tell anyone how to do their business (well... maybe I am...) but $6B for $TERN seems cheap.
Maybe what we heard from Lilly's Jake van Naarden last week is true, t…↗
Mar 25
Adam Feuerstein ✡️ — @JacobPlieth FTC would have blocked a $NVS bid for $TERN, I think. $BMY buying $TERN made a lot of sense, and it needs it more than Merck. Maybe a higher bid is coming.↗
Jacob Plieth — Worth $6bn to $MRK? $TERN data from #ASH25 $ELVN↗
January 2026 · 3 mentions
Jan 9
Jacob Plieth — Still not convinced by $ELVN? Via @ApexOnco -> https://t.co/98kEmPBZfk $TERN↗
Jan 9
Jacob Plieth — Notable that $ELVN didn't split out the 60mg from the 120mg results. Did 60mg actually do better than 80mg?? All quite bizarre, but stock +50% so what do I know! $TERN↗
Jan 9
Jacob Plieth — OK then, let's play the "selected doses" game $ELVN $TERN https://t.co/qoY08k7Lfi↗
December 2025 · 9 mentions
Dec 12
Jacob Plieth — @NotJanetYellen7 So this idea that $ELVN comes after $TERN, that's been a thing for how long? A week?↗
Dec 9
Jacob Plieth — If you enjoyed #ASH25 you can catch up on all @ApexOnco coverage, including previews, here -> https://t.co/XIQrEeKMwY $TERN $JNJ $LLY $CGEM $ONC $NRIX $PFE $REGN $KURA↗
Dec 9
Jacob Plieth — $TERN wins #ASH25, via @ApexOnco -> https://t.co/6mQGwnSUq8 $ELVN $NVS↗
Dec 9
Jacob Plieth — $ELVN vs $TERN: game over? #ASH25 https://t.co/2jLNdqFSFM↗
November 2025 · 1 mention
Nov 27
Jacob Plieth — If you need some biotech reading over Thanksgiving check out @ApexOnco previews of #ASH25 --> https://t.co/cqsR1AVbPH Starts in just over a week! $ACLX $ONC $CRVS $TERN $KURA $S…↗
Dec 9
Jacob Plieth — $TERN looks like the winner of #ASH25 then, +37% yesterday, and +600% since November's abstract lift. Funny, when I last wrote about it in May it was worth a quarter of $ELVN↗
Dec 8
Adam Feuerstein ✡️ — $TERN investor dinner tonight in Orlando via Jefferies is standing room only. They ran out of seats and chicken, stragglers only get dinner rolls thrown to them.↗
Dec 8
Adam Feuerstein ✡️ — $BMY should buy $TERN
$BMY needs to buy $TERN
If everyone else can make M&A predictions on this site, so can I.↗
Dec 8
Adam Feuerstein ✡️ — $TERN Results in Terns leukemia drug study suggest it could be a successor to Novartis $NVS blockbuster https://t.co/51H9opufDT #ASH25↗
Dec 4
Adam Feuerstein ✡️ — What to expect at the #ASH25 meeting, and some thoughts on the FDA’s Richard Pazdur https://t.co/2Upwf0Oh9M $TERN $INCY $ACLX $FULC↗